Last Updated: November 19, 2026

Details for Patent: 9,701,709

« Back to Dashboard


Which drugs does patent 9,701,709 protect, and when does it expire?

Patent 9,701,709 protects SKYCLARYS and is included in one NDA.

This patent has fifty-six patent family members in thirty-five countries.

Summary for Patent: 9,701,709
Title:2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Abstract:The present invention relates generally to the compound:
Inventor(s):Eric Anderson, Xiaofeng Liu, Andrea Decker
Assignee: Solvias AG , Reata Pharmaceuticals Holdings LLC
Application Number:US14/625,829
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Dosage form;
Patent landscape, scope, and claims:

US Patent 9,701,709: Polymorphic Forms of Omaveloxolone, Claim Scope and Generic-Entry Risk

US Patent 9,701,709 covers solid-state forms of omaveloxolone, also known as bardoxolone methyl or CDDO-methyl ester, rather than the compound’s basic chemical structure. Its strongest enforceable subject matter is Claim 1, which covers a defined polymorphic form identified by a characteristic X-ray powder diffraction signal and a glass-transition temperature of approximately 153°C. Claims 6-13 extend that form to pharmaceutical compositions, while Claims 14-15 cover treatment of inflammation- or oxidative-stress-related conditions, including dermatitis.

The patent creates a formulation and solid-state barrier for products using the claimed form. It does not by itself provide comprehensive protection for every crystalline, amorphous, solvated, or therapeutic-use version of omaveloxolone. The principal commercial risk is an ANDA applicant using a different polymorph, amorphous form, hydrate, solvent-free form, or manufacturing process and certifying noninfringement.

What drug and active ingredient does US Patent 9,701,709 cover?

The patent covers polymorphic forms of omaveloxolone, a synthetic oleanane triterpenoid also known as bardoxolone methyl and CDDO-methyl ester. Omaveloxolone activates the Nrf2 pathway and has been developed for inflammatory, oxidative-stress, and mitochondrial disorders.

The FDA approved omaveloxolone under the trade name Skyclarys for adults and adolescents aged 16 years or older with Friedreich's ataxia. The approved product is an oral capsule. The patent claims are broader in disease scope than the approved indication, but broad method claims do not automatically convert into Orange Book-listed protection for the commercial product (FDA, 2023).

Patent identity and commercial relevance

Item Analysis
U.S. patent US 9,701,709 B2
Issue date July 11, 2017
Covered substance Polymorphic forms of omaveloxolone/CDDO-methyl ester
Primary protection Solid-state form defined by PXRD and thermal properties
Related dosage forms Oral, topical, parenteral, and other formulations under dependent claims
Approved product associated with active ingredient Skyclarys oral capsules
FDA-approved indication Friedreich's ataxia
Relevant FDA pathway NDA approval under section 505(b)(1)
Generic pathway ANDA under section 505(j)
Biosimilar pathway Not applicable because omaveloxolone is a small molecule

What does Claim 1 of US Patent 9,701,709 protect?

Claim 1 covers a polymorphic form of omaveloxolone having:

  1. An X-ray powder diffraction pattern using CuKα radiation with a halo peak at approximately 14° 2θ; and
  2. A glass-transition temperature, or Tg, of approximately 153°C.

The combination is important. A product generally must satisfy both the structural identity of the claimed omaveloxolone form and the specified solid-state characteristics. A material with a 14° 2θ feature but a materially different Tg may fall outside the claim. The reverse also applies.

The use of a “halo peak” indicates that Claim 1 is directed to an amorphous or predominantly amorphous solid rather than a conventional highly crystalline polymorph. Amorphous materials produce diffuse diffraction halos instead of a dense series of sharp Bragg peaks. The Tg limitation supplies a second analytical fingerprint.

Claim 1 scope

Claim element Legal and technical significance
Polymorphic form Limits the claim to a particular solid-state version of the active ingredient
Compound formula Requires the claimed omaveloxolone molecular structure
CuKα PXRD Establishes the analytical measurement method
Halo peak at about 14° 2θ Identifies the diffraction signature
Tg of about 153°C Adds a thermal-property limitation
No dosage-form limitation The solid form can be present in bulk drug substance or a formulation

The phrase “about” creates a range that would be interpreted in light of the specification, analytical error, experimental conditions, and prosecution history. A generic applicant would likely compare PXRD and DSC data against the patent’s examples and claim construction record rather than rely on a single nominal value.

What do Claims 2 through 5 protect?

Claims 2-5 cover separate solvated or solvent-containing solid forms. Each claim is defined by a distinct PXRD pattern.

Claim Claimed form Identifying PXRD peaks
2 Solvate Approximately 5.6, 10.6, and 14.6° 2θ
3 Solvate Approximately 7.0, 7.8, 11.9, 13.9 double peak, and 16.0° 2θ
4 Acetonitrile hemisolvate Approximately 7.5, 15.6, and 16.6° 2θ
5 Solvate Approximately 9.3, 9.5, 10.5, 13.6, and 15.6° 2θ

These claims are composition-of-matter claims to defined solid forms. They do not require a pharmaceutical composition, a particular dosage form, or a therapeutic use.

Why the solvate claims matter

Solvates can arise during crystallization, isolation, drying, storage, or formulation. An acetonitrile hemisolvate, for example, contains acetonitrile in a defined stoichiometric relationship with the drug substance. If a manufacturing process produces one of these solvates before conversion to the final form, infringement analysis may extend to the drug-substance manufacturing step.

The claims do not cover every solvate of omaveloxolone. They require the specified PXRD characteristics and, for Claim 4, the acetonitrile hemisolvate designation. A hydrate, ethanol solvate, methanol solvate, or unrelated crystalline form would require separate analysis.

What pharmaceutical compositions are protected by Claims 6 through 13?

Claims 6-13 protect compositions containing the polymorphic form of Claim 1. The active ingredient must consist of the Claim 1 form, together with a pharmaceutically acceptable carrier.

The composition claims cover:

  • Broad administration routes under Claim 7;
  • Oral, intraarterial, intravenous, or topical administration under Claim 8;
  • Oral administration under Claim 9;
  • Capsules, tablets, syrups, suspensions, emulsions, solutions, solid dispersions, wafers, and elixirs under Claim 10;
  • Topical administration under Claim 11;
  • Lotions, creams, gels, oils, ointments, salves, emulsions, solutions, and suspensions under Claim 12; and
  • An active-ingredient concentration of approximately 0.01% to 5% by weight under Claim 13.

Composition claim hierarchy

Claim Scope
6 Pharmaceutical composition containing the Claim 1 polymorph
7 Broad list of administration routes and delivery approaches
8 Oral, intraarterial, intravenous, or topical formulation
9 Oral formulation
10 Specified oral and liquid dosage forms
11 Topical formulation
12 Specified topical dosage forms
13 0.01% to 5% active ingredient by weight

Claims 6-13 are narrower than Claim 1 because they require the polymorph to be present in a pharmaceutical composition. They may be important against a finished dosage-form product even if the generic applicant argues that its bulk drug substance is not covered by the solid-form claim. The composition claims, however, remain dependent on use of the specific Claim 1 form.

What methods of treatment are protected by Claims 14 and 15?

Claim 14 covers treating a condition associated with inflammation or oxidative stress by administering a therapeutically effective amount of the Claim 1 polymorph. The listed conditions are:

  • Prostate cancer;
  • Dermatitis;
  • Sepsis;
  • Pulmonary inflammation;
  • Pulmonary fibrosis;
  • Chronic obstructive pulmonary disease;
  • Asthma;
  • Mucositis; and
  • Ocular inflammation.

Claim 15 narrows Claim 14 to dermatitis.

These are method-of-use claims, not claims to the disease itself or to omaveloxolone generally. Infringement requires use of the claimed polymorphic form for a listed condition. A product label that omits the patented use can reduce induced-infringement exposure, although prescribing practice, promotional activity, product literature, and evidence of intended use remain relevant.

The claims do not expressly cover Friedreich's ataxia, the FDA-approved Skyclarys indication. That distinction is commercially significant. The patent may protect the approved product’s solid form, but the listed method claims do not directly recite the approved indication.

When does US Patent 9,701,709 lose exclusivity?

The patent issued on July 11, 2017. Its nominal U.S. patent term is generally calculated from the earliest effective nonprovisional or international filing date in the priority chain, rather than from the issue date. Based on the family timing associated with this solid-form patent, the expected nominal expiration is in 2029, before any applicable patent-term adjustment or extension.

Milestone Date or period
Patent issuance July 11, 2017
Nominal patent-term endpoint Approximately 2029
Earliest possible generic filing Four years before nominal expiration for a Paragraph IV ANDA
Potential 30-month stay Available if timely infringement litigation follows a Paragraph IV notice
Post-expiration entry Subject to other unexpired listed patents and regulatory exclusivity

The exact enforceable endpoint depends on the patent’s terminal disclaimer status, patent-term adjustment, and any patent-term extension. A patent-term extension is generally unavailable for a patent that was not listed as covering the approved drug or that does not satisfy the statutory requirements for the relevant regulatory approval.

FDA regulatory exclusivity is separate from patent exclusivity. Skyclarys received approval in 2023. New chemical entity exclusivity ordinarily lasts five years, subject to the statutory Paragraph IV exception allowing an ANDA filing after four years. That exclusivity period does not extend US 9,701,709.

What is the Orange Book status of US Patent 9,701,709?

Orange Book listing must be assessed against the approved NDA and the patent’s claims. A patent covering an active ingredient, formulation, or method of use may be listed only if it meets FDA’s listing standards and is submitted by the NDA holder.

The patent’s claims are potentially relevant to an oral omaveloxolone product because Claim 1 covers a solid form and Claims 6, 9, and 10 cover oral compositions. The method claims are less directly aligned with Skyclarys because they recite inflammatory and oxidative-stress conditions rather than Friedreich's ataxia.

The commercial consequences differ by listing status:

Status Consequence
Listed patent ANDA applicant must submit Paragraph I, II, III, or IV certification
Unlisted patent No Orange Book certification is required for that patent
Paragraph IV certification NDA holder may sue within 45 days and trigger a potential 30-month stay
Paragraph III certification Generic waits until patent expiration
Method claim not directed to approved use May have limited Orange Book relevance for the approved product

A patent not listed in the Orange Book can still support a later patent-infringement action if the generic product infringes. It does not, however, receive the same automatic ANDA-stay mechanism tied to an Orange Book Paragraph IV notice.

How strong is the patent estate for omaveloxolone?

US 9,701,709 is technically narrow but potentially valuable. Solid-form claims can be difficult to design around when the innovator’s commercial product uses the claimed form. They are less powerful when the active ingredient can be manufactured and formulated in a different stable form without loss of bioavailability or manufacturability.

Strength factors

  1. Claim 1 combines PXRD and Tg limitations, creating a reproducible analytical fingerprint.
  2. Claims 2-5 cover several solvent-containing forms that may arise during manufacturing.
  3. Composition claims extend the estate from bulk drug substance to finished products.
  4. The claims do not depend on a particular dose, excipient, capsule strength, or brand.
  5. The patent can create process-development costs even if a generic ultimately avoids literal infringement.

Weakness factors

  1. Claims 2-5 are separate solid-form claims and do not automatically cover the Claim 1 form.
  2. The claims use approximate analytical values that may invite disputes over measurement conditions and tolerances.
  3. Claim 1 appears directed to an amorphous form, which may be avoidable through a crystalline or differently solvated form.
  4. The treatment claims do not recite Friedreich's ataxia.
  5. Patent validity may be challenged based on prior disclosure of amorphous omaveloxolone, solvent-mediated crystallization, or routine solid-form screening.
  6. A generic applicant can pursue a non-infringing ANDA formulation while relying on a different drug-substance form.

Which companies are challenging omaveloxolone exclusivity?

The principal commercial challenger would be a generic manufacturer filing an ANDA for omaveloxolone capsules. Publicly identified Paragraph IV challengers and patent litigation should be verified against current FDA Orange Book records and PACER docket data before being used in an investment or litigation decision.

No biosimilar challenge is relevant. Omaveloxolone is a chemically synthesized small molecule, so competition will proceed through the generic-drug pathway rather than the biosimilar pathway under the Public Health Service Act.

Biogen became the commercial owner of Reata Pharmaceuticals in 2023. That transaction transferred Skyclarys commercialization and the associated intellectual-property strategy to Biogen (Biogen, 2023).

What generic launch scenarios exist?

Scenario 1: Paragraph IV challenge to the solid-form patent

A generic applicant may argue that its omaveloxolone drug substance does not have the Claim 1 PXRD/Tg profile and does not use any solvate covered by Claims 2-5. The applicant may file a Paragraph IV certification if the patent is listed.

The NDA holder could sue for infringement within 45 days. A timely action may delay FDA approval for up to 30 months, subject to court decisions and statutory exceptions.

Scenario 2: Non-infringing crystalline form

The generic may select a crystalline form with sharp PXRD peaks, avoiding the halo pattern in Claim 1. It would then need to demonstrate acceptable stability, dissolution, bioavailability, and manufacturing consistency.

Scenario 3: Form conversion before formulation

A manufacturer may isolate or receive the active ingredient as a solvate but convert it to another form before tableting or encapsulation. The conversion step would require close analysis because transient formation of a claimed solvate can create process-infringement issues.

Scenario 4: Skinny-label strategy

If the patent were listed only for a method of use not covered by the generic label, an ANDA applicant could seek approval with a carved-out indication. This strategy is less relevant to the specific method claims here because they do not recite Friedreich's ataxia.

What manufacturing and geographic barriers exist?

The patent is a U.S. right. It can block manufacture, use, sale, offer for sale, or importation of an infringing product into the United States. It does not independently block manufacture and sale in Europe, Japan, China, or other jurisdictions.

The strongest manufacturing barrier is analytical control. A manufacturer must control:

  • Solvent content;
  • Drying conditions;
  • Relative humidity;
  • Milling and particle-size reduction;
  • Heating history;
  • Amorphous-to-crystalline conversion;
  • Storage temperature; and
  • Form conversion during granulation or encapsulation.

A generic developer should characterize the drug substance at multiple process stages. PXRD, differential scanning calorimetry, thermogravimetric analysis, Karl Fischer water analysis, residual-solvent testing, and solid-state NMR may be relevant. Patent infringement cannot be determined from the formulation label alone.

What patent litigation and settlement issues matter?

A settlement involving US 9,701,709 could establish an authorized generic date, a license for a specified polymorph, a field-of-use restriction, or a manufacturing license. The most important documents are:

  • Paragraph IV notice letter;
  • Complaint and answer;
  • Claim-construction orders;
  • Invalidity contentions;
  • Settlement agreement;
  • FDA-approved license terms, if disclosed; and
  • Any district-court judgment or Federal Circuit decision.

A settlement may resolve the patent case without eliminating other patent barriers. The relevant patent landscape must therefore include approved-product patents, formulation patents, method-of-use patents, and any later-issued continuation patents.

Key Takeaways

  • US 9,701,709 is a solid-state patent for omaveloxolone, not a basic composition-of-matter patent.
  • Claim 1 is the central claim because it covers a form defined by a 14° 2θ halo peak and Tg of approximately 153°C.
  • Claims 2-5 cover distinct solvates, including an acetonitrile hemisolvate.
  • Claims 6-13 extend protection to formulations, particularly oral and topical products.
  • Claims 14-15 cover treatment of specified inflammatory and oxidative-stress conditions, including dermatitis, but do not expressly recite Friedreich's ataxia.
  • The patent’s nominal term reaches approximately 2029, subject to the official term calculation and any adjustment.
  • Generic risk is highest if Skyclarys uses the claimed amorphous form and the patent is listed in the Orange Book.
  • A non-infringing crystalline form or different solvate is the most direct design-around route.
  • Biosimilar competition is irrelevant because omaveloxolone is a small molecule.
  • Biogen is the current commercial owner following its acquisition of Reata Pharmaceuticals.

FAQs

Can a generic company avoid US 9,701,709 by using crystalline omaveloxolone?

Potentially. A crystalline form with PXRD and thermal properties outside the asserted claim limitations may avoid literal infringement, but the full manufacturing process and any equivalents argument must be evaluated.

Does the patent cover every amorphous form of omaveloxolone?

No. Claim 1 is tied to a particular PXRD halo and Tg. Other amorphous forms may fall outside the claim if their analytical properties materially differ.

Does Claim 4 cover all acetonitrile-containing omaveloxolone products?

No. Claim 4 is directed to an acetonitrile hemisolvate with specified PXRD peaks. The solvent ratio and diffraction profile are material limitations.

Can the patent block a topical omaveloxolone product?

Claims 11-13 may apply if the topical product contains the Claim 1 polymorph and satisfies the relevant formulation limitations. Claims 14-15 may also apply if the product is used for the claimed conditions.

Is a Paragraph IV certification required if the patent is not listed in the Orange Book?

No. A nonlisted patent does not require an Orange Book certification, although the patent owner may still pursue infringement litigation based on the generic product or its manufacturing process.

References

Biogen Inc. (2023). Biogen to acquire Reata Pharmaceuticals, expanding growth and commercial opportunities. https://investors.biogen.com

Food and Drug Administration. (2023). Skyclarys (omaveloxolone) prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugsatfda

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,701,709: Polymorphic forms of omaveloxolone. U.S. Department of Commerce.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,701,709

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Us SKYCLARYS omaveloxolone CAPSULE;ORAL 216718-001 Feb 28, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,701,709

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2841445 ⤷  Start Trial CA 2024 00015 Denmark ⤷  Start Trial
European Patent Office 2841445 ⤷  Start Trial PA2024511 Lithuania ⤷  Start Trial
European Patent Office 2841445 ⤷  Start Trial LUC00340 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.